ERBB2 and cancer: Our data demonstrate that cellular senescence‐based ultrasound‐targeted imaging can identify reversible senescence and evaluate LAP resistance effectively in HER2+ breast cancer cells, which has the potential to improve cancer treatment outcomes by altering therapeutic strategies ahead of aggressive recurrences.